推荐产品
ligand
BocA1V2PF2
质量水平
表单
powder
反应适用性
reagent type: ligand
官能团
carboxylic acid
储存温度
2-8°C
SMILES字符串
C[C@H](NC(OC(C)(C)C)=O)C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(O)=O)CC2=CC=C(C=C2)F)=O)=O)C3CCCCC3)=O
InChI
1S/C30H43FN4O7/c1-18(32-29(41)42-30(2,3)4)25(36)34-24(20-9-6-5-7-10-20)27(38)35-16-8-11-23(35)26(37)33-22(28(39)40)17-19-12-14-21(31)15-13-19/h12-15,18,20,22-24H,5-11,16-17H2,1-4H3,(H,32,41)(H,33,37)(H,34,36)(H,39,40)/t18-,22-,23-,24-/m0/s1
InChI key
LNJCHGKSSPMNRM-IMNFJDCFSA-N
应用
BocA1V2PF2 is an in silico-derived inhibitor of apoptosis protein (IAP)-recruiting ligand for targeted protein degradation and SNIPER (specific and non-genetic IAP-dependent protein erasers) development, launched in partnership with ComInnex. Learn more about the novel IAP ligands generated through virtual screening of AVP mimetics in our Technology Spotlights. A C-terminal variant of BocA1V2PF2 is also available as A1V2PF2-NHEt (916714).
BocA1V2PF2 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining
SNIPER and PROTAC® degrader libraries: Degrader Building Blocks
917443BocA1V2PF2-NHC6-NH2
917699 BocA1V2PF2-NHC10-NH2
917958 BocA1V2PF2-NHPEG1-NH2
916692 BocA1V2PF2-NHPEG3-NH2
BocA1V2PF2 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining
SNIPER and PROTAC® degrader libraries: Degrader Building Blocks
917443BocA1V2PF2-NHC6-NH2
917699 BocA1V2PF2-NHC10-NH2
917958 BocA1V2PF2-NHPEG1-NH2
916692 BocA1V2PF2-NHPEG3-NH2
其他说明
法律信息
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
相关产品
产品编号
说明
价格
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Tasuku Ishida et al.
SLAS discovery : advancing life sciences R & D, 26(4), 484-502 (2020-11-05)
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to
Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein
Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持